{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"34"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Duration of Complete response (CR) from base line in months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5"},{"groupId":"OG001","value":"8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Duration of Partial response (PR) from baseline months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG002","value":"4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"Duration of Progressive Disease (PD)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"Time from response to progression. Response is defined by RANO: Complete Response (CR)= no change in size of T1-gadolinium-enhancing (T1-Gd+) disease, stable or reduced T2/FLAIR signal, no new lesion, no corticosteroid use, and stable or improved clinical status; Partial Response (PR)= ≥50% change in size of T1-Gd+ disease, stable or reduced T2/FLAIR signal, no new lesion, stable or reduced corticosteroid use, and stable or improved clinical status; Stable Disease (SD)= \\<50% reduction to \\<25% increase size of T1-Gd+ disease, stable or reduced T2/FLAIR signal, no new lesion, stable or reduced corticosteroid use, and stable or improved clinical status; Progressive Disease (PD)= ≥25% increase size of T1-Gd+ disease, or increased T2/FLAIR signal, or presence of new lesion, or worsening clinical status.","groups":[{"description":"Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle\n\nResearch Bloods\n\nEncorafenib: 450mg QD 28 day cycle\n\nBinimetinib: 45mg BID 28 day cycle\n\nResearch Bloods: Baseline; pre-cycle 3; Pre-cycle 7; off Treatment\n\nTumor Tissue: at time of surgery contrast enhancing and non enhancing tumor; 20 unstained slides","id":"OG000","title":"Treatment Cohort 1 AA & GBM"},{"description":"Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle\n\nResearch Bloods\n\nEncorafenib: 450mg QD 28 day cycle\n\nBinimetinib: 45mg BID 28 day cycle\n\nResearch Bloods: Baseline; pre-cycle 3; Pre-cycle 7; off Treatment\n\nTumor Tissue: at time of surgery contrast enhancing and non enhancing tumor; 20 unstained slides","id":"OG001","title":"Treatment Cohort 2 Anaplastic PXAs"},{"description":"Encorafenib 450mg QD Binimetinib 45mg BID 28 day cycle\n\nResearch Bloods\n\nEncorafenib: 450mg QD 28 day cycle\n\nBinimetinib: 45mg BID 28 day cycle\n\nResearch Bloods: Baseline; pre-cycle 3; Pre-cycle 7; off Treatment\n\nTumor Tissue: at time of surgery contrast enhancing and non enhancing tumor; 20 unstained slides","id":"OG002","title":"Treatment Cohort 3 Other Tumors"}],"paramType":"NUMBER","populationDescription":"Each row represents the type of response. The number in that row equals the duration of response in months (mean) for all patients in cohort who had a response of the row title. There were 5 patients and only 3 patients had a response of CR or PR","reportingStatus":"POSTED","timeFrame":"up to 3 year","title":"Duration of Response - Complete and Partial","type":"SECONDARY","unitOfMeasure":"months"}